InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Announcements

- Current share price for MYX : $2.420

ASX company news and announcements for Mayne Pharma Group Limited (MYX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mayne Pharma Group Limited (MYX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mayne Pharma Group Limited (MYX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mayne Pharma Group Limited (MYX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$198 Investor presentation 26 Oct 2026 8:50AM $2.450 $2.420 fallen by 1.22%
$198 Mayne Pharma reports unaudited Q1 FY27 results 26 Oct 2026 8:49AM $2.450 $2.420 fallen by 1.22%
$198 2026 Notice of Annual General Meeting and shareholder pack 19 Oct 2026 9:15AM $2.520 $2.420 fallen by 3.97%
$198 MYX settles US patent litigation re Imvexxy with Teva USA 16 Oct 2026 9:43AM $2.490 $2.420 fallen by 2.81%
$198 Supreme Court Decision in Cosette Proceedings 14 Oct 2026 1:29PM $2.540 $2.420 fallen by 4.72%
$198 Trading Halt 14 Oct 2026 8:20AM $2.540 $2.420 fallen by 4.72%
$198 Fulfilment of Imvexxy post-marketing study requirements 9 Oct 2026 9:41AM $2.750 $2.420 fallen by 12%
$198 Notification of cessation of securities - MYX 7 Oct 2026 4:30PM $2.830 $2.420 fallen by 14.49%
$198 MYX settles US patent litigation re Imvexxy with Sun Pharma 30 Sep 2026 9:49AM $2.830 $2.420 fallen by 14.49%
$198 Mayne Pharma announces legal settlement 28 Sep 2026 9:45AM $2.810 $2.420 fallen by 13.88%
$198 Date for Annual General Meeting 28 Sep 2026 9:42AM $2.810 $2.420 fallen by 13.88%
$198 MYX signs licence agreement for Blissel in Australia 15 Sep 2026 9:50AM $3.060 $2.420 fallen by 20.92%
$198 Notification of cessation of securities - MYX 8 Sep 2026 6:42PM $3.160 $2.420 fallen by 23.42%
$198 Notification regarding unquoted securities - MYX 8 Sep 2026 6:41PM $3.160 $2.420 fallen by 23.42%
$198 Application for quotation of securities - MYX 28 Aug 2026 5:29PM $3.010 $2.420 fallen by 19.60%
$198 2026 Full Year Results Investor Presentation 27 Aug 2026 8:44AM $3.170 $2.420 fallen by 23.66%
$198 2026 Corporate Governance Statement and Appendix 4G 27 Aug 2026 8:43AM $3.170 $2.420 fallen by 23.66%
$198 2026 Full Year Results Media Release 27 Aug 2026 8:42AM $3.170 $2.420 fallen by 23.66%
$198 2026 Appendix 4E and Annual Report 27 Aug 2026 8:40AM $3.170 $2.420 fallen by 23.66%
$198 Notification of date for release of FY26 results 21 Aug 2026 12:56PM $3.270 $2.420 fallen by 25.99%
$198 Upcoming presentation of Imvexxy clinical data 20 Aug 2026 8:59AM $3.230 $2.420 fallen by 25.08%
$198 Mayne Pharma launches Investor Hub 18 Aug 2026 9:16AM $3.300 $2.420 fallen by 26.67%
$198 Initial Director's Interest Notice 14 Aug 2026 5:13PM $3.200 $2.420 fallen by 24.38%
$198 Mayne Pharma Bioshares Summit Presentation 5 Aug 2026 5:20PM $3.130 $2.420 fallen by 22.68%
$198 Notification of cessation of securities - MYX 5 Aug 2026 5:14PM $3.130 $2.420 fallen by 22.68%

1 - 25 of 910 results

Page 1 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.